证券代码：603270 证券简称：金帝股份 公告编号：2026-019 关于为子公司提供担保进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 山东金帝精密机械科技股份有限公司 近日，公司与北京银行股份有限公司聊城分行签署了《最高额保证合同》，由公司对博源节能在该行于 2026年2月26日至2029年2月25日期间内发生的债务提供连带责任保证担保，提供的担保金额为2,000万 元。博源节能对本次担保不提供反担保。 （二）内部决策程序 公司于2025年12月9日召开第三届董事会第二十一次会议、2025年12月25日召开2025年第四次临时股东 会，均审议通过了《关于公司2026年度申请综合融资额度及担保额度的议案》，具体内容详见公司于 2025年12月10日披露的《山东金帝精密机械科技股份有限公司关于2026年度申请综合融资额度及担保额 度的公告》（公告编号：2025-117）。截至本公告披露日，公司本年度对外担保情况均为对公司全资或 控股子公司及其下属企业的担保，均在经公司股东会审议通过的授权担保额度范 ...

Group 1: Resumption of Trading - Yongtai Technology has terminated the purchase of 25% equity in Yongtai High-tech from CATL, leading to the resumption of its stock trading [1] - Runze Technology plans to acquire 42.56% equity in Guangdong Runhui through a convertible bond issuance, further integrating IDC and AIDC business resources, resulting in stock resumption [1] Group 2: Capital Increase and Restructuring - Zongshen Power intends to swap its motorcycle engine business with Longxin General's general machinery business, which is expected to constitute a major asset restructuring [2] - Nanjing Chemical Fiber plans to acquire 100% equity in Nanjing Craft through asset swaps, share issuance, and cash payments [3] - Southwest Securities plans to raise no more than 6 billion yuan through a private placement [4] Group 3: Equity Transfer and Buyback - Hemai Co., Ltd. has a planned agreement to transfer 5.99% equity from Hainan Xinhai [5] - Luxshare Precision has conducted its first share buyback of 9.9 million shares, with a total transaction amount of nearly 500 million yuan [6] Group 4: External Investment and Daily Operations - Gaode Infrared has signed a contract for a complete equipment system worth 1.851 billion yuan, accounting for 69% of its audited revenue for 2024 [7] - Shenghong Technology now holds 100% equity in SPMY, with the target company becoming its FPC/PCB production base in Malaysia [7] - BGI Genomics plans to sell 100% equity in Complete Genomics for 50 million USD and adjust the licensing of CoolMPS sequencing technology [8] - Aolian Electronics' controlling shareholder, Ruiying Assets, has terminated the control transfer with Chaocheng Innovation [9] - Frontier Biotech has signed a licensing agreement with GlaxoSmithKline, receiving a 40 million USD upfront payment and 13 million USD in milestone payments [9] - Baili Tianheng's clinical trial for iza-bren (EGFR×HER3 dual antibody ADC) for locally advanced or metastatic triple-negative breast cancer has reached its primary endpoint in interim analysis [9] - Donghong Co., Ltd. has won a procurement project for pressure steel pipes and accessories worth 353 million yuan [10] - ST Xintong's subsidiary has signed a server procurement contract worth 400 million yuan [11] Group 5: Performance Changes - Yingshi Innovation expects a net profit of 964 million yuan in 2025, a year-on-year decrease of 3.08% [12]

Group 1 - The company, Jiangxi Jindalai Environmental Protection Co., Ltd., has approved an external investment plan to invest in Yunnan Jici Medical Technology Co., Ltd. [2][3] - The investment will be executed in three phases, with a total investment of RMB 150 million in the first phase, followed by RMB 50 million in the second phase, and the remaining funds after obtaining new drug clinical research approval [3][4] - The company aims to establish a concerted action relationship with Hu Min to jointly control Jici Medical in major decisions [3][4] Group 2 - The changes in the investment plan are expected to enhance the company's risk resistance and align with its long-term strategic development, without adversely affecting daily operations [5] - The investment is sourced from the company's own funds, which will not impose significant short-term cash flow pressure [8] - The company acknowledges the uncertainties and risks associated with drug development, including potential delays in clinical trials and regulatory approvals [9][10]

Core Viewpoint - The company plans to establish a wholly-owned subsidiary, Yiwu Gaofa Automotive Control Systems Co., Ltd., with an investment not exceeding RMB 100 million to deepen its domestic market presence and meet customer demands [2][3]. Group 1: Investment Overview - The total planned investment for the new subsidiary is up to RMB 100 million, which will cover fixed asset investments, research and development, and working capital [3][6]. - The investment decision was approved by the company's fifth board meeting on February 10, 2026, and does not require shareholder approval as it does not meet the threshold for such [2][4][14]. - The company will implement the investment in phases based on market demand and business progress, with the flexibility to adjust investment amounts and methods as necessary [3][7]. Group 2: Subsidiary Details - The proposed subsidiary will be registered with a capital of RMB 10 million, subject to adjustments based on actual operational needs [5]. - The subsidiary's business scope includes manufacturing and research of automotive parts, integrated circuit design and manufacturing, and software development [5]. Group 3: Impact on the Company - This investment is aimed at enhancing the company's existing business structure and market positioning without significantly impacting its financial status or operational results [7].

Core Viewpoint - The company Baifang Co., Ltd. (八方股份) announced that its wholly-owned subsidiary Baifang (Tianjin) Electric Technology Co., Ltd. plans to jointly invest in a new entity, Tianjin Trade, with two individuals, which aligns with the company's long-term strategic development [1] Group 1 - Baifang Tianjin will hold a 60% stake in the new Tianjin Trade, while the individual investors Gao Zhiming and Wang Zhimin will hold 30% and 10% respectively [1] - The registered capital for Tianjin Trade is set at 20 million RMB [1] - This investment is aimed at resource integration and market expansion, which is consistent with the company's strategic goals [1] Group 2 - The investment will utilize idle funds and is not expected to have a significant impact on the company's financial and operational status [1] - There are no concerns regarding the potential harm to the interests of the company and its shareholders [1]

Core Viewpoint - The company announced the termination of the investment agreement with AstraZeneca due to significant market changes and high risks in the vaccine industry [1] Group 1: Investment Agreement - The company planned to establish a joint venture with AstraZeneca focusing on vaccines, with a registered capital of 345 million RMB (approximately 50 million USD) [1] - Both the company and AstraZeneca were to hold 50% equity in the joint venture, with a total investment estimated at around 400 million USD (approximately 2.76 billion RMB) [1] - The decision to terminate the investment was made after careful evaluation and discussions among the parties involved, acknowledging the high risks associated with new investments in the vaccine sector [1] Group 2: Board Decisions - The termination of the investment agreement was approved during the company's eighth board meeting held on February 6, 2026 [1] - The board authorized the management to finalize and sign the relevant termination agreements with the partners [1]

Group 1 - The company, Nanchang Mining Machinery Group Co., Ltd., has approved an investment of $30 million to acquire a 10% stake in Eagle Canyon Gold Limited through its wholly-owned subsidiary, NMS International Holding Pte. Ltd. [1][2][3] - The overall valuation of Eagle Canyon Gold Limited is set at $30 million, with the investment being contingent upon the completion of various preconditions, including internal restructuring and regulatory approvals [2][4][5]. - The investment aims to expand the company's overseas market presence and enhance its competitiveness in the mineral resources sector [15][18][19]. Group 2 - The transaction does not constitute a major asset restructuring or related party transaction, and it requires approval from domestic regulatory authorities for the outbound investment [2][3][17]. - The investment will provide the company with priority cooperation rights for mining projects, thereby injecting new growth momentum into its core business [18][19]. - The company plans to utilize the funds from the investment for restructuring and operational expenses related to the mining projects [5][18]. Group 3 - The investment is part of the company's strategic plan to extend its industrial chain and align with its long-term development strategy [15][18]. - The company has engaged intermediaries to conduct asset evaluations for Eagle Canyon Gold Limited, which are still ongoing [4][5]. - The investment is expected to facilitate the company's transition from traditional equipment sales to broader mining operation services, thus expanding its business ecosystem [18][19].

Group 1 - The company held its 27th meeting of the 5th Board of Directors on February 4, 2026, to discuss and approve a new investment proposal [2][4][9] - The company will establish a wholly-owned subsidiary, Guangdong Youfa Pipe Industry Technology Co., Ltd., with a registered capital of RMB 500 million, funded entirely by cash [4][11][15] - The investment is within the board's approval authority and does not require shareholder approval, nor does it constitute a related party transaction or a major asset restructuring [10][12][13] Group 2 - The investment aims to enhance the financial strength and competitiveness of the subsidiary, optimize its asset-liability structure, and facilitate business operations [4][15] - The company has cumulatively invested RMB 1,012.03 million in the past 12 months, which is within 10% to 50% of its latest audited net assets [12][16] - The funding for the investment will come from the company's own funds, and it is expected to positively impact the company's overall competitiveness and strategic development [15][17]

Core Viewpoint - The company, Shanghai Metters Bonway Apparel Co., Ltd., is progressing with its investment in a joint venture, Guizhou Meibang New Energy Textile and Apparel Technology Co., Ltd., with specific performance commitments outlined for its subsidiary, Shanghai Bangyun Industrial Co., Ltd. [2][3] Group 1: Investment Overview - The company approved the establishment of a joint venture with Guizhou Textile Industry Development Group Co., Ltd. and Guizhou Agricultural Modernization Development Equity Investment Fund Partnership, with a registered capital of RMB 100 million [3]. - The capital contributions are as follows: Guizhou Textile Group will contribute RMB 51 million (51%), Guizhou Agricultural Fund will contribute RMB 39 million (39%), and Shanghai Bangyun will contribute RMB 10 million (10%) [3]. Group 2: Management and Performance Commitments - Mr. Zhou Chengjian has been appointed as the general manager of the joint venture, with Shanghai Bangyun acting as the performance commitment party, responsible for achieving the agreed performance targets [4][5]. - If the joint venture fails to meet the performance targets during the assessment period, Shanghai Bangyun must compensate the shortfall in net profit within 30 days after the audit [4][5]. Group 3: Joint Venture Registration - The joint venture, Guizhou Meibang New Energy Textile and Apparel Technology Co., Ltd., has completed its business registration and obtained a business license [5][6]. - The company is registered with a capital of RMB 100 million and is located in Dafa County, Bijie City, Guizhou Province, with a variety of business activities including textile processing and apparel manufacturing [6].

Group 1 - The board of directors of Guizhou Yongji Printing Co., Ltd. approved the second phase of the acquisition of Phytoca Holdings, with the final purchase price set at AUD 38,509,532.35 (approximately RMB 187 million), reflecting an increase of AUD 17,728,049.95 (approximately RMB 86 million) from the initial estimate [24][26]. - The second phase of the acquisition is part of a broader investment strategy aimed at expanding the company's presence in the regulated pharmaceutical market in Australia, enhancing long-term profitability and competitive strength [27][28]. - The first phase of the equity transfer was completed on April 7, 2025, with Yongji Health holding 60% of Phytoca Holdings, which will be included in the company's consolidated financial statements [11][12]. Group 2 - The second phase of the equity purchase price is determined based on a dynamic adjustment formula linked to Phytoca Holdings' audited EBIT for the fiscal year 2025, which was AUD 8,481,083.16 (approximately RMB 41 million) [14][17]. - The company plans to apply for a merger loan of RMB 100 million to finance part of the second phase acquisition, with a loan term of 5 years and an interest rate of 3.8% [20][24]. - The acquisition is expected to optimize the company's financing structure and support its strategic goals, with no significant financial risks anticipated from the merger loan [28].